Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 vs Platinum-based Chemotherapy in EGFR-mutated NSCLC
NCT06927986Phase 3Recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of CPO301 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoint: Progression-Free Survival at 1.5 years. Started Mar 2025; status: recruiting.
02
Drugs
CPO301
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06927986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06927986.